Core Points - The first stock of the Sci-Tech Innovation Growth Tier, He Yuan Bio, has attracted significant market attention during its subscription process [2][3] - Many investors faced issues with subscription due to insufficient permissions, highlighting the varying service quality among brokerage firms [1][5] Company Overview - He Yuan Bio is the first company to successfully pass the review and obtain registration approval under the new fifth set of standards for the Sci-Tech Innovation Board [3] - The total issuance amount for He Yuan Bio is 89.45 million shares, with 14.31 million shares available for online subscription [3] - The maximum subscription limit for investors is 14,000 shares, requiring a minimum market value of 140,000 yuan in the Shanghai market [3] - He Yuan Bio focuses on the research and development of plant molecular medicine technology and products, specifically using a rice endosperm cell expression system [3] - The core product, HY1001, has completed Phase III clinical trials, achieving both primary and secondary endpoints [3] Financial Performance - He Yuan Bio has not yet achieved profitability, with projected revenues of 13.40 million yuan, 24.26 million yuan, 25.22 million yuan, and 12.71 million yuan for the years 2022 to 2025 [3] - The net profit attributable to the parent company is projected to be -144 million yuan, -187 million yuan, -151 million yuan, and -81.63 million yuan for the same period [3] Subscription Process and Challenges - Investors must first open trading permissions for the Sci-Tech Innovation Board and sign a risk disclosure agreement to participate in the Growth Tier [4] - The requirements for opening permissions include maintaining an average asset of at least 500,000 yuan over the past 20 trading days, having at least two years of trading experience, and achieving a risk assessment level of C4 or above [4] - The quality of service from brokerage firms significantly impacts the ease of permission opening, with some firms providing proactive communication and guidance while others do not [5] Market Response and Future Outlook - Investors have called for improved services, suggesting the establishment of a subscription alert mechanism to prevent permission issues from hindering new stock opportunities [6] - Other companies in the Growth Tier, such as Xi'an Yicai and Bibete, are also set to launch subscriptions soon, indicating ongoing interest in this market segment [9]
科创成长层首股禾元生物打新，券商提醒缺位让投资者遭遇权限门槛